Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study
Annals of Hematology · 2026
DOI: 10.1007/s00277-026-06808-5 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Hematology, 2026. Verfasst von Yun Wang und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Centre for Cancer, Sun Ya…. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing Xisike Clinical Oncology Research Foundation.
Abstract (Originalsprache)
Background
Adding daratumumab to initial therapy in randomized controlled trials (RCTs) for newly diagnosed multiple myeloma (MM) enhances deep remission and prolongs progression-free survival (PFS). Given the differences between trial-eligible and real-world patients, and healthcare access variability in developing countries, real-world data are essential to complement RCT evidence.
Methods
We analyzed 761 newly diagnosed MM patients treated with (n = 177) or without (n = 584) daratumumab as first-line therapy from 2017 to 2023 across southern China. Propensity score matching (PSM) generated cohorts of 158 and 278 patients, respectively, matched for stage, cytogenetic abnormalities, and regimen type. Responses were evaluated per International Myeloma Working Group criteria, and measurable residual disease (MRD) was assessed via next-generation multiparameter flow cytometry.
Results
The daratumumab group demonstrated significantly higher rates of ≥ very good partial response (85.0% vs. 61.3%; P < 0.001) and MRD negativity (73.0% vs. 51.9%; P = 0.024) at the end of induction. Additionally, 3-year PFS (75.6% vs. 55.0%, hazard ratio [HR] 0.49, 95% confidence interval [95% CI] 0.36–0.66, P < 0.001) and overall survival (OS) rates (78.3% vs. 74.4%; HR 0.56 [95% CI 0.36–0.86], P = 0.008) were superior in the daratumumab group, and these results remained consistent after PSM. Daratumumab improved PFS in patients with gain/amp(1q21) but not in those with del17p or t(4;14). Survival benefit was also observed in the addition of daratumumab to bortezomib/lenalidomide/dexamethasone combined treatment subgroup.
Conclusion
In real-world settings, daratumumab-based first-line therapy improved the depth of response, PFS, and OS, though not all patients benefited.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Centre for Cancer, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510…
- Department of Hematology, The First Affiliated Hospital of Guangxi Medical University Guangxi, Nanning, P. R. China.
- Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, P. R. China.
- Department of Hematologic Oncology, Centre for Haematology, Hainan Cancer Hospital, Haikou, P. R. China.
- Department of Hematology, Shenzhen Second People's Hospital, Shenzhen, P. R. China.
- Department of Hematology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, P. R. China.
Förderung
- Beijing Xisike Clinical Oncology Research Foundation
Zitieren
APA
Wang, Y., Chen, X., Liang, Q., Wang, W., Luo, J., Luo, L., Feng, R., Wei, Y., Tian, Y., Du, X., Huang, Z., Hu, G., Fu, X., Tao, S., Zhou, J., Peng, H., Su, Y., Zhang, H., Dong, M., …, & Xia, Z. (2026). Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study. Annals of Hematology. https://doi.org/10.1007/s00277-026-06808-5
Vancouver
Wang Y, Chen X, Liang Q, Wang W, Luo J, Luo L, et al. Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study. Annals of Hematology. 2026. doi:10.1007/s00277-026-06808-5
BibTeX
@article{Wang2026,
author = {Wang, Yun and Chen, Xiaoqin and Liang, Qi and Wang, Weida and Luo, Jun and Luo, Lin and Feng, Ru and Wei, Yongqiang and Tian, Yuyang and Du, Xin and Huang, Zhenqian and Hu, Guoyu and Fu, Xiangjun and Tao, Shi and Zhou, Jihao and Peng, Hongling and Su, Yongzhong and Zhang, Hongyu and Dong, Min and Lan, Mei and Sun, Zhiqiang and Wang, Xiuju and Zhou, Hui and Zhong, Liye and Peter Gale, Rober and Liang, Yang and Xia, Zhongjun},
title = {Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study},
journal = {Annals of Hematology},
year = {2026},
doi = {10.1007/s00277-026-06808-5}
}
EUVIMED